JP2009533472A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533472A5
JP2009533472A5 JP2009505614A JP2009505614A JP2009533472A5 JP 2009533472 A5 JP2009533472 A5 JP 2009533472A5 JP 2009505614 A JP2009505614 A JP 2009505614A JP 2009505614 A JP2009505614 A JP 2009505614A JP 2009533472 A5 JP2009533472 A5 JP 2009533472A5
Authority
JP
Japan
Prior art keywords
alkyl
group
halo
alkoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009505614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/066478 external-priority patent/WO2007121279A2/en
Publication of JP2009533472A publication Critical patent/JP2009533472A/ja
Publication of JP2009533472A5 publication Critical patent/JP2009533472A5/ja
Pending legal-status Critical Current

Links

JP2009505614A 2006-04-13 2007-04-12 癌治療法 Pending JP2009533472A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79184106P 2006-04-13 2006-04-13
PCT/US2007/066478 WO2007121279A2 (en) 2006-04-13 2007-04-12 Cancer treatment method

Publications (2)

Publication Number Publication Date
JP2009533472A JP2009533472A (ja) 2009-09-17
JP2009533472A5 true JP2009533472A5 (enExample) 2010-05-20

Family

ID=38610376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505614A Pending JP2009533472A (ja) 2006-04-13 2007-04-12 癌治療法

Country Status (4)

Country Link
US (1) US20090203718A1 (enExample)
EP (1) EP2012587A2 (enExample)
JP (1) JP2009533472A (enExample)
WO (1) WO2007121279A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595755A (en) * 2009-04-16 2013-07-26 Merck Sharp & Dohme Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
EP2475789A4 (en) * 2009-09-09 2013-12-18 Quintiles Transnat Corp METHODS FOR PREDICTING SENSITIVITY OF DISEASE OR DISORDER TO RECEPTOR TYROSINE KINASE INHIBITOR THROUGH MUTATION ANALYSIS IN PIK3CA GENE
EP2550269B1 (en) 2010-03-23 2016-03-23 Scinopharm Taiwan Ltd. Process and intermediates for preparing lapatinib
WO2012026511A1 (ja) * 2010-08-27 2012-03-01 協和発酵キリン株式会社 医薬組成物
ITMI20110894A1 (it) 2011-05-20 2012-11-21 Italiana Sint Spa Impurezza del lapatinib e suoi sali
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR100815681B1 (ko) * 2000-06-30 2008-03-20 글락소 그룹 리미티드 퀴나졸린 디토실레이트 염 화합물
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
JP2007523956A (ja) * 2004-02-25 2007-08-23 ダナ−ファーバー キャンサー インスティテュート インク. 腫瘍細胞増殖を阻害するための方法
US20050272637A1 (en) * 2004-04-22 2005-12-08 Oregon Health & Science University Compositions and methods for modulating signaling mediated by IGF-1 receptor and erbB receptors

Similar Documents

Publication Publication Date Title
JP2009533472A5 (enExample)
JP2005534623A5 (enExample)
JP2010504344A5 (enExample)
JP2010532768A5 (enExample)
JP2002080453A5 (enExample)
JP2012525431A5 (enExample)
JP2017526677A5 (enExample)
JP2017523167A5 (enExample)
JP2005502661A5 (enExample)
JP2004525179A5 (enExample)
JP2004517049A5 (enExample)
JP2008513498A5 (enExample)
JP2017511794A5 (enExample)
JP2017537882A5 (enExample)
JP2005504100A5 (enExample)
JP2011502958A5 (enExample)
JP2009506039A5 (enExample)
JP2008255122A5 (enExample)
JP2011520906A5 (enExample)
JP2010525056A5 (enExample)
JP2013518129A5 (enExample)
JP2017505762A5 (enExample)
JP2009502743A5 (enExample)
JP2017511378A5 (enExample)
JP2007519753A5 (enExample)